With a small laboratory established in 1881 by the Health Department, the long journey of disease prevention and vaccine production started, with the small pox vaccine produced for the first time in Egypt in 1893, followed by the rabies vaccine in Kasr El Ainy – Pasteur Institute in 1907.

In 1940 “King Fouad Laboratory for Sera and Vaccines” was established in Agouza district (Giza - Egypt), for the production of some bacterial and viral vaccines in addition to some antisera like tetanus and diphtheria antitoxins.

In 1948 “King Farouk the 1st – Laboratory for Biological Products” was established for BCG production, virus diagnosis, blood banking, plasma production and biochemistry research.

In 1968 the Animal Laboratory House was established in Helwan district (Cairo - Egypt) for the breeding of laboratory animals and production of some antisera like snake and scorpion ant venom.

In 1971 the regional WHO Reference Lab for Virus Research was established.

In 1973 the “Egyptian Organization for Biological Products and Vaccines” VACSERA was established under the presidential decree # 94.

Ever since, VACSERA has been dedicated to fulfill Egypt's requirements for vaccines and biological products.

In 1979 VACSERA was declared as a commercial economic organization according to the ministerial decree # 1039. In the same year the rift valley fever virus was successfully isolated and the rift valley vaccine for veterinary use was produced.

Throughout the years many products were included in VACSERA product portfolio and several laboratories and production plants were established.

Laboratories for plasma fractionation as well as production of therapeutically fluids were developed.

During the last decades VACSERA in cooperation with some international organizations established the Plasmapheresis Unit of VACSERA Blood Bank, the National Control Laboratory for Biological and the Central Filling Department.

New technologies were implemented for production development, including fermentation technology for the production of tetanus vaccine in 1979.

In 1983 diphtheria and pertussis vaccines were produced using the same technology.

In 1985 a Research Center was established for the diagnosis of Homophiles Influenza type b, rheumatic fever and bilharzias is, as well as the production of vaccines using genetic engineering technology.

In 1990 VACSERA Information Technology Unit was established, followed by the Quality Assurance Department in 1994.

From 1997 till 2002 VACSERA scientists in the Scientific Research Academy of Egypt successfully registered about 18 patents. Recently, two new patents were registered abroad in the United States and Jordan.